Sarcopenia is associated with reduced overall survival time and progression-free survival in lung cancer patients. Sarcopenia is an independent predictor of poor survival particularly in specific high-risk subgroups. When assessing for sarcopenia it is crucial to include assessment of muscle function in evaluating the prognosis of lung cancer.
Shen et al. (Wed,) studied this question.